Will the Treat and Reduce Obesity Act pass?

The bill has bipartisan support and has been introduced multiple times. Its passage would require Medicare to cover FDA-approved anti-obesity medications. Timing is uncertain, but the political momentum has grown as GLP-1 medications have gained public attention. Even if passed, implementation would take time.

Can my doctor prescribe Ozempic for weight loss if I have diabetes?

If you have type 2 diabetes, Ozempic is prescribed on-label for glucose control — weight loss is a known beneficial effect. Insurance typically covers it for this indication. If you don't have diabetes, Ozempic for weight loss is off-label and less likely to be covered.

What's a prior authorization and how long does it take?

Prior authorization is your insurance company's requirement for your doctor to justify the prescription before they'll cover it. It involves submitting clinical documentation. Timelines vary: some are resolved in 24-72 hours; others take 2-4 weeks. Urgent/expedited reviews can be requested.

Are there any GLP-1 medications that are cheaper?

Liraglutide (Saxenda) is sometimes available at lower cost and has more generic competition potential. Oral semaglutide (Rybelsus) may have different coverage depending on your plan. Compounded versions during shortage periods can be $200-500/month. No GLP-1 is truly 'cheap' at U.S. list prices.

Does Insurance Cover GLP-1 Medications? A State-by-State Reality Check

Whether insurance covers your GLP-1 medication depends on a frustrating matrix of variables: your plan type (commercial, Medicare, Medicaid, employer self-insured), your state, the specific medication, your diagnosis (diabetes vs obesity), and your prescriber's willingness to fight prior authorization battles. About 40% of commercial insurance plans now cover at least one GLP-1 for weight management, up from under 20% in 2022, but that still leaves the majority of Americans without straightforward coverage for obesity treatment.

Commercial Insurance

Coverage is expanding but inconsistent. Large employer plans increasingly cover Wegovy or Zepbound, often after prior authorization. Smaller employer plans and individual marketplace plans are less likely to include anti-obesity medications in their formularies. Self-insured employers (who design their own benefits) are the most variable — some have added GLP-1 coverage proactively; others explicitly exclude weight management medications.

Key variables: does the plan cover anti-obesity medications as a category? Is there a prior authorization requirement? What's the copay tier? Are there quantity limits or step-therapy requirements (must try other interventions first)?

Medicare

Medicare Part D does not cover drugs for weight loss. Period. This is due to a 2003 law that explicitly excludes weight management medications. Ozempic and Mounjaro are covered under Medicare Part D when prescribed for type 2 diabetes. The distinction is the indication, not the drug itself.

Medicare Advantage (Part C) plans have more flexibility and some have begun covering anti-obesity medications as supplemental benefits, but this is not universal. Check your specific plan.

Medicaid

State Medicaid programs vary enormously. Some cover GLP-1s for both diabetes and obesity; others cover only for diabetes; some have restricted formularies. Several states have added anti-obesity medication coverage in recent years as the evidence base has grown. Contact your state Medicaid office or check the formulary online.

Strategies to Get Coverage

Document everything. Your medical record should include: current BMI, weight history, documented weight-related comorbidities (hypertension, type 2 diabetes or prediabetes, sleep apnea, dyslipidemia, NAFLD), documented attempts at lifestyle modification (diet, exercise, behavioral counseling), and any previous weight management attempts.

Get the right diagnosis code. E66.01 (morbid obesity due to excess calories) may get different coverage than E66.09. Your prescriber's coding matters.

Appeal denials. First-level appeals succeed about 40-50% of the time. External appeals (to an independent review organization) can overturn decisions the insurer won't. Many patients give up after the first denial — persistence pays.

Switch formulations. If your plan denies Wegovy but covers Ozempic for an on-label diabetes indication (and you have diabetes or prediabetes), the same molecule becomes accessible through a different coverage pathway.

The Employer Angle

If you work for a large self-insured employer that doesn't cover anti-obesity medications, consider reaching out to HR or benefits leadership. Frame it as a cost argument: treating obesity prevents costly downstream conditions (diabetes, cardiovascular disease, joint replacement). Some employers have changed their coverage after employee advocacy. The ROI data from preventive health is compelling.

What's Changing

The regulatory landscape is shifting. The FDA's recognition of obesity as a chronic disease, growing employer coverage, and pending Medicare legislation all point toward broader access. Competition from new entrants (oral semaglutide at higher doses, retatrutide, amycretin) may eventually drive prices down. But for now, navigating the current system requires active advocacy.